DNA integrity as a potential marker for stool-based detection of colorectal cancer

Clinical Chemistry

Volumn 49, Issue 7, 2003, Pages 1058-1065

  Boynton, Kevin A ^a   Summerhayes, Ian C ^b   Ahlquist, David A ^c   Shuber, Anthony P ^a  

^a Exact Sciences Corporation   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DNA FRAGMENT;

ARTICLE; CANCER DIAGNOSIS; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DNA DETERMINATION; DNA ISOLATION; DNA PURIFICATION; FECES ANALYSIS; HUMAN; MOLECULAR WEIGHT; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; TUMOR CELL;

COLORECTAL NEOPLASMS; DNA; FECES; HUMANS; MOLECULAR WEIGHT; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0037934747     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.7.1058     Document Type: Article

References (29)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;15-36.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
3. Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin 1997;47:154-60.
4. Schnoll-Sussman F, Markowitz AJ, Winawer SJ. Screening and surveillance for colorectal cancer. Semin Oncol 2000;27:10-21.
5. Ahlquist DA. Fecal occult blood testing for colorectal cancer. Can we afford to do this? Gastroenterol Clin North Am 1997;26:41-55.
6. Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001;345:555-60.
7. Ahlquist DA, Klee GG, McGill DB, Ellesfon RD. Colorectal cancer detection in the practice setting. Impact of fecal blood testing. Arch Intern Med 1990;150:1041-5.
8. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 2002;315:157-68.
9. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res 2001;7:1118-26.
10. Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:1219-27.
11. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
12. Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:858-65.
13. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol 2000;31:51-7.
14. Kumi-Diaka J, Sanderson NA, Hall A. The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP. Biol Cell 2000;92:595-604.
15. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int 2000;50:273-9.
16. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-6.
17. Ishida M, Gomyo Y, Ohfuji S, Ikeda M, Kawasaki H, Ito H. Evidence that expression of a mutated p53 gene attenuates apoptotic cell death in human gastric intestinal-type carcinomas in vivo. Jpn J Cancer Res 1997;88:468-75.
18. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A 1996;93:7950-4.
19. Ward RL, Todd AV, Santiago F, O'Connor T, Hawkins NJ. Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer 1997;79:1106-13.
20. Sugamura K, Makino M, Kaibara N. Apoptosis as a prognostic factor in colorectal carcinoma. Surg Today 1998;28:145-50.
21. Payne CM, Bernstein H, Bernstein C, Garewal H. Role of apoptosis in biology and pathology: resistance to apoptosis in colon carcinogenesis. Ultrastruct Pathol 1995;19:221-48.
22. Garewal H, Bernstein H, Bernstein C, Sampliner R, Payne C. Reduced bile acid-induced apoptosis in "normal" colorectal mucosa: a potential biological marker for cancer risk. Cancer Res 1996;56:1480-3.
23. Bernstein C, Bernstein H, Garewal H, Dinning P, Jabi R, Sampliner RE, et al. A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies.
24. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
25. Cordon-Cardo C, Cote RJ, Sauter G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol Suppl 2000;82-93.
26. Goessl C, Muller M, Heicappell R, Krause H, Miller K. DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci 2001;945:51-8.
27. Hamdy FC. Prognostic and predictive factors in prostate cancer. Cancer Treat Rev 2001;27:143-51.
28. Bodis S, Siziopikou KP, Schnitt SJ, Harris JR, Fisher DE. Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer 1996;77:1831-5.
29. Neurath MF, Finotto S, Fuss I, Boirivant M, Galle PR, Strober W. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 2001;22:21-6.